Skip to content

A feasibility study of fMRI-neurofeedback in Parkinson*s disease

A feasibility study of fMRI-neurofeedback in Parkinson*s disease - Brain self-regulation for Parkinson*s

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53752
Enrollment
12
Registered
2023-05-15
Start date
2023-06-01
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Shaking palsy

Interventions

The fMRI neurofeedback (NF) sessions will include anatomical scans, an fMRI localizer (inactive bar thermometer shown whilst patients move the dominant hand, alternating with rest periods) and neuro

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Diagnosis of Parkinson*s disease according to MDS clinical diagnostic criteria (Postuma et al., 2015). - Disease stage 1-3 according to the Hoehn and Yahr Scale

Exclusion criteria

Exclusion criteria: - Exclusion criteria for MRI (e.g., cardiac pacemaker, certain metallic implants) - History of psychotic disorder, bipolar disorder, or psychotic depression - Current use of illegal drugs (any in the last four weeks) - Current excessive alcohol consumption that interferes with daily functioning - Advanced cognitive impairment (MoCA

Design outcomes

Primary

MeasureTime frame
The region of interest fMRI data will be analysed with the appropriate parametric tests for activation and general linear model analysis will be performed as implemented in the Brainvoyager software. This will assess neurofeedback performance and changes in brain activation over time.

Secondary

MeasureTime frame
Correlational analysis will be performed on demographic and clinical data (MoCA score) to assess association with neurofeedback performance.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)